Supplementary Materials

This PDF file includes:

  • Fig. S1. Synthesis of DSPE-PEG-S2P and its characterization by 1H NMR spectrum.
  • Fig. S2. Assessment of NP stability.
  • Fig. S3. Change of NP diameter over time.
  • Fig. S4. Encapsulation efficiency of siRNA in S2P0 and S2P50 NPs.
  • Fig. S5. NP morphology.
  • Fig. S6. Serum stability of siRNA-loaded S2P50 NPs.
  • Fig. S7. Silencing of luciferase in HeLa-Luc cells by S2P0-siLuc NPs.
  • Fig. S8. Effect of S2P50-siLuc NPs on cell viability in vitro.
  • Fig. S9. Apoptosis assays.
  • Fig. S10. Proliferation assays.
  • Fig. S11. NP uptake and stabilin-2 expression in macrophages and nonmacrophage cell types.
  • Fig. S12. Time course of Dy647 fluorescence in whole blood of mice injected with free Dy647-siRNA or Dy647-siRNA in S2P0 and S2P50 NPs.
  • Fig. S13. Gating strategy for aortic macrophages.
  • Fig. S14. Biodistribution of Alexa 647–conjugated S2P0- and S2P50-siCamk2g NPs.
  • Fig. S15. FACS analysis of fluorescent NPs in splenocytes 24 hours after NP injection into WD-fed Ldlr−/− mice.
  • Fig. S16. Effect of siCamk2g S2P50 NPs on macrophage efferocytosis.
  • Fig. S17. CaMKIIγ silencing with NPs enhances efferocytosis as assessed by flow cytometry.
  • Fig. S18. CaMKIIγ expression in lesional SMCs and ECs in NP-treated Ldlr−/− mice.
  • Fig. S19. CaMKIIγ expression in splenic macrophages in NP-treated Ldlr−/− mice.
  • Fig. S20. CaMKIIγ expression in liver macrophages in NP-treated Ldlr−/− mice.
  • Fig. S21. Metabolic parameters and blood cell counts of WD-fed Ldlr−/− mice treated with PBS or S2P50 NPs containing control siRNA or siCamk2g.
  • Fig. S22. Histological analyses of the major organs in NP-treated Ldlr−/− mice.
  • Fig. S23. Plasma TNF-α and IL-12 concentrations in mice injected with PBS, empty S2P50 NPs, or S2P50-siCamk2g NPs.
  • Fig. S24. Summary scheme of the study.

[Download PDF]